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Abstract 15 
The aim of this study was to propose a procedure for optimising the cost-effectiveness of vector 16 
borne disease surveillance using a scenario tree model and cost-effectiveness analysis. The 17 
surveillance systems for Bluetongue Virus serotype 8 (BTV-8) implemented in Switzerland and 18 
Belgium were used as examples. In twenty four different, simulated population structures, passive 19 
surveillance and five designs of active surveillance were investigated. The influence of surveillance 20 
system design and parameters such as farmer disease awareness, veterinary disease awareness, herd 21 
and within-herd design prevalence on the overall surveillance system sensitivity were assessed. 22 
Furthermore, the cost-effectiveness of mandatory and voluntary vaccination regimes in relation to 23 
disease surveillance was investigated.  24 
Under the assumption that BTV-8 manifests clinically, freedom from disease in a population can be 25 
established with almost certainty over the period of one year using clinical surveillance alone. 26 
Additional investment in active surveillance would therefore economically only be justified, if no 27 
clinical manifestation is suspected or other surveillance objectives are to be provided such as early 28 
detection. The best cost-effectiveness is obtained by sampling more herds rather than more animals 29 
within a herd. Mandatory vaccination reduces the cost of surveillance by 0.26 € per vaccine and 30 
voluntary vaccination only marginally reduces the cost of risk-based surveillance, by reducing the 31 
population at risk. Finally, in populations with predominantly dairy cattle, bulk-tank milk testing is the 32 
method of choice to actively demonstrate freedom from disease. 33 
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Introduction 37 
The emergence of Bluetongue virus serotype 8 (BTV-8) in northern Europe in 2006, lead to the 38 
European Commission regulation 1266/2007 on the surveillance of Bluetongue (European 39 
Commission, 2007; Mehlhorn et al., 2007; Toussaint et al., 2006). Based on this regulation, several 40 
countries implemented a range of surveillance strategies from 2006 onwards in order to detect 41 
circulation of BTV or alternatively prove freedom from infection with BTV after implementing 42 
mitigation and surveillance strategies. The original requirement to detect a prevalence of 0.005 in 43 
the bovine with 95% confidence was relaxed in May 2012 requesting to detect a prevalence of only 44 
0.05. 45 
Conventionally, surveillance approaches are divided into passive and active surveillance. Passive 46 
surveillance mainly consists of mandatory reporting of clinical suspect cases by owners and 47 
veterinarians while active surveillance is most commonly implemented as a strategy decided by the 48 
competent veterinary services, and with a certain objective on the short, mid- and long term. Active 49 
surveillance implies the whole range of activities needed to guarantee these objectives such as 50 
appropriate sample selection, collection and laboratory analysis as well as follow-up of results and 51 
interventions. In contrast, passive surveillance heavily relies on disease awareness of the involved 52 
stakeholders (Hadorn et al., 2008) and is considered to cover the entire target population. Active 53 
surveillance is designed to represent the surveyed population according to a set target (i.e. 54 
confidence level at a given design prevalence). The most generic form of active surveillance would be 55 
a random sample, however, to reduce cost, as well as increase sensitivity of detection, risk-based 56 
surveillance has been applied in many settings (Alban et al., 2008; Calvo-Artavia et al., 2012; Hadorn 57 
et al., 2009; Welby et al., 2013). The technical performance of a risk-based surveillance component 58 
applied to establish freedom from infection can be expressed by its sensitivity, i.e. the probability to 59 
detect at least one case if the disease is present at a predefined design prevalence.  60 
Active surveillance, if designed to have a high sensitivity, incurs substantial costs for sampling and 61 
testing. The decision on how much resources are spent for surveillance of a specific disease is the 62 
result of political, technical and financial considerations. In order to guide such decisions, we propose 63 
here a combination of scenario tree modelling as first described Martin et al. (Martin et al., 2007) 64 
and cost-effectiveness analysis (CEA). CEA is a method of comparing the cost and effectiveness of 65 
two or more health care alternatives to aid decisions on resource allocation (Clasen et al., 2007; 66 
Eichler et al., 2004; Hutubessy et al., 2003; McEwan, 2012; Russel et al., 1996). It directly relates the 67 
financial and scientific implications of different interventions in a systemic way (Levin, 1995). 68 
The aim of the present study was to propose a process for optimising surveillance performance and 69 
costs using a scenario tree model and CEA in sequence. The application of this approach is illustrated 70 
using BTV-8 as an example, because there is potential for BTV to reoccur in North-western Europe. 71 
The BTV-8-surveillance implemented in Belgium (BE) and Switzerland (CH) in 2011 and 2012 was 72 
assessed by Nafzger (Nafzger, 2016), and the benefit of surveillance for BTV-8 has been 73 
demonstrated (Häsler et al., 2012; Pinior et al., 2015), but it was also shown that the continuation of 74 
that surveillance and intervention program might not be economically justified (Häsler et al., 2012).  75 
The question arises whether surveillance for BTV could be more cost-effective. In the present study, 76 
surveillance is optimised from two distinct perspectives: first with the objective to identify the most 77 
cost-effective system to demonstrate freedom from disease, and second under the assumption that 78 
active surveillance is mandatory in addition to clinical surveillance (as prescribed by the EC 79 
regulation, European Commission, 2007).  80 
Material & Methods 81 
Here we first describe the generic stochastic scenario tree model implemented in R (Core R Team, 82 
2013, code available upon request). It is followed by a deterministic model for the cost-effectiveness 83 
analysis implemented in Excel (Microsoft Corporation, 2010, supplementary data). Finally, the 84 
example for Bluetongue serotype 8 is described with the data used for the analysis and optimisation 85 
of the surveillance approach. 86 
Scenario tree model of disease surveillance for freedom from 87 
disease 88 
The confidence level in a surveillance system to demonstrate freedom from disease can be measured 89 
as sensitivity to detect at least one infected animal at a given design prevalence in a given 90 
geographical unit. Martin and co-workers (Martin et al., 2007) proposed scenario tree models to 91 
compute this sensitivity. Such a tree consists of a sequence of nodes, with branches dividing the 92 
reference population into subpopulations. Nodes are categorized as infection, detection or risk 93 
nodes, where infection nodes specify the infection status of a unit, detection nodes define all events 94 
that must take place for the detection of the infection, and risk nodes represent those factors that 95 
affect the probability of a unit being infected or detected. For the present study, risk factors were 96 
considered at herd level as represented in Fig. 1. The relative risk distributions were computed by 97 
combining expert opinions collected by Nafzger (Nafzger, 2016) and are presented in the 98 
supplementary material. The model was implemented at country level for passive surveillance, 99 
namely clinical surveillance (CLIN), while for active surveillance three different components were 100 
considered using different diagnostic methods and matrices: i) blood samples and testing with an 101 
ELISA for BTV-8-specific serum antibodies (ELISA), ii) blood samples and testing with an RT-PCR assay 102 
specific for BTV-RNA (RT-PCR), and iii) bulk milk samples and testing with an ELISA for BTV-8-specific 103 
milk antibodies (BMT). For CLIN the testing procedure was a sequence of events determined by the 104 
probability of a farmer to detect the disease and call a veterinarian (farmer’s disease awareness, 105 
fDA), the probability of a veterinarian to take a sample and submit it for testing (veterinarian’s 106 
disease awareness, vDA) and the sensitivity of the confirmatory RT-PCR. At herd level, the sensitivity 107 
(SeH) was computed according to 108 
    𝑆𝑆𝑆𝑆𝑆𝑆 = 1− (1− 𝑓𝑓𝑓𝑓𝑓𝑓 × 𝑣𝑣𝑓𝑓𝑓𝑓 × 𝑆𝑆𝑆𝑆𝑃𝑃𝑃𝑃𝑃𝑃)𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚×𝑁𝑁𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖×𝑃𝑃∗𝐴𝐴 , (1) 109 
where morb is the morbidity, NinHerd is the number of animals in a herd, and P*A is the within-herd 110 
design prevalence. The exponent is rounded to the next larger integer. Because for clinical 111 
surveillance all animals are assumed to be looked at during clinical inspection by farmers, there is no 112 
sampling fraction included in the Equation �𝑛𝑛𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖
𝑁𝑁𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖
= 1�. For active surveillance, the SeH was 113 
computed in analogy, including the sampling fraction: 114 
 𝑆𝑆𝑆𝑆𝑆𝑆 = 1− �1− 𝑆𝑆𝑆𝑆𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 × 𝑛𝑛𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑁𝑁𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖�𝑁𝑁𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖×𝑃𝑃∗𝐴𝐴. (2) 115 
 Where SeTest is the sensitivity of the diagnostic test, ninHerd is the number of animals sampled in a 116 
herd, NinHerd is the number of animals in a herd, and P*A is the within-herd design prevalence. The 117 
exponent is rounded to the next larger integer. 118 
The contribution to surveillance sensitivity from the risk-based sampling of different population 119 
strata was computed and aggregated at population level as component sensitivity (CSe), as 120 
previously described (Martin et al., 2007; Welby et al., 2013). For combinations of two surveillance 121 
components, e.g. clinical (CSeclinic) and an active component (CSeactive), the system sensitivity (SSe) was 122 
computed according to 123 
 𝑆𝑆𝑆𝑆𝑆𝑆 = 1− [1− 𝐶𝐶𝑆𝑆𝑆𝑆𝑐𝑐𝑐𝑐𝑐𝑐𝑛𝑛𝑐𝑐𝑐𝑐] × [1− 𝐶𝐶𝑆𝑆𝑆𝑆𝑎𝑎𝑐𝑐𝑇𝑇𝑐𝑐𝑎𝑎𝑇𝑇]. (3) 124 
Cost-effectiveness analysis 125 
CEA was applied to assess the efficiency of different alternatives of disease surveillance systems. The 126 
goal of CEA is to assess if the value of an intervention justifies its cost. The method relates the 127 
financial implications and the technical performance of a surveillance design in a systemic way (Levin, 128 
1995), and was implemented in analogy to Guo and co-workers (Guo et al., 2014). The authors 129 
describe the basic concept and consider direct costs of surveillance, in addition to the direct 130 
consequential costs and indirect costs of an outbreak. In the present study, only direct costs of 131 
surveillance were considered as total annual costs. Furthermore, the calculation was restricted to the 132 
variable costs, which included: Cost of information campaign, cost of labour, cost of material, cost of 133 
transportation, cost of diagnostic tests, cost of communication and confirmation of results, and 134 
miscellaneous costs. If not stated otherwise, costs and activities were presumed to be at an annual 135 
basis. The scenario tree model provided the data for sampling and testing activities as well as the 136 
corresponding surveillance system sensitivity (SSe). It was iterated 1500 times and the resulting 137 
median sampling activity was converted into total costs. Then the different surveillance designs were 138 
compared on a plot where the x-axis are median total costs and the y-axis median SSe. Due to the 139 
threshold of at least 95% for the SSe used in the surveillance optimisation (see below), only a small 140 
portion of the theoretical space for optimisation is used. The spreadsheet to perform the cost-141 
effectiveness analysis and detailed instructions are available as supplementary data.  142 
Surveillance optimisation for Bluetongue 143 
Factors considered for surveillance of Bluetongue and associated costs in various countries were 144 
collected by Nafzger (Nafzger, 2016). In the present project a generic summary of these data was 145 
used: The parameters used for the scenario tree model are given in Table 1, while the surveillance 146 
specific costs and time expenditures for the cost calculation are given in Tables 2 and 3. Where 147 
deemed appropriate, parameters were modelled stochastically using a pert distribution.  148 
Surveillance optimisation 149 
For the present study, surveillance was optimised from two distinct perspectives: first with the 150 
objective to identify the most cost-effective system to demonstrate freedom from disease, and 151 
second under the assumption that active surveillance was mandatory in addition to clinical 152 
surveillance ( as prescribed by the EC regulation, European Commission, 2007). While clinical 153 
surveillance leaves little room for optimisation, active surveillance requires some strategic decisions 154 
and depends on active implementation by the veterinary services. The aim of the following 155 
surveillance optimisation process was to inform the design of an active surveillance system for 156 
Bluetongue. Many different surveillance designs are possible. But, the study focusses on five possible 157 
designs that represent some fundamental choices that can be considered by policy makers. The 158 
designs compared were (1) a random sample, (2) risk-based surveillance targeting only high risk 159 
herds, (3) voluntary vaccination with risk-based surveillance targeting all non-vaccinated herds, (4) 160 
voluntary vaccination with risk-based surveillance targeting non-vaccinated herds at high risk, and (5) 161 
mandatory vaccination with risk-based surveillance targeting herds at high risk.  162 
Active surveillance was only simulated on the cattle population as required by the EC 1266/2007, and 163 
reported to have been conducted in many European countries (European Commission, 2007; 164 
Nafzger, 2016). From here onwards, the term “sensitivity” as the technical performance of a 165 
surveillance system or a component thereof shall be named SSe or CSe respectively (as described 166 
above for the scenario tree model). In contrast, the description of the sensitivity of the model to its 167 
input parameters (as explained below) shall be denominated “model sensitivity”. To compare the 168 
surveillance designs, the CSe for blood serology by ELISA, blood virus detection by RT-PCR or BMT 169 
was assessed. 170 
The technical performance of surveillance components is strongly affected by the population 171 
structure, i.e. the distribution of risk factors amongst the different subpopulations at risk. However, 172 
in practice in a given territory under surveillance, this structure is given and not subject to change or 173 
decisions. Hence, in order to make generic statements on how to design a surveillance system for 174 
optimal cost-effectiveness, we applied active surveillance components to a set of standard 175 
population structures reflecting livestock population distributions in different countries or 176 
geographical units. Twenty-four combinations were evaluated using four characteristics of a standing 177 
population (a) a population with a majority of cattle versus a majority of sheep, (b) primarily milk vs 178 
primarily meat production, and (c) a population with primarily small herds (median= 30 animals/ 179 
herd) versus primarily large herds (median= 100 animals/ herd).  Furthermore, either 5, 10 or 40% of 180 
the population were assumed to be exposed to high infection risk, respectively. The combinations 181 
considered are listed in Table 4. The focus of active surveillance exclusively on cattle was maintained 182 
throughout. 183 
In addition, voluntary vaccination was assumed to attain a 10% protective coverage of the 184 
population, and mandatory vaccination 75%. We calculated the necessary number of herds and 185 
animals to sample for attaining a CSe-threshold of 95% or 99%. Five hundred iterations were 186 
computed with combinations of the number of animals to sample per herd between 2 and 20, and 187 
the number of herds to sample between 50 and 300 (by increments of 5 herds). 188 
Two combinations of the number of animals in a herd and the number of herds required to sample in 189 
order to obtain 95% CSe were identified: (point a) sampling as few animals in a herd as possible 190 
(between 0 and 20), and (point b) sampling as few herds as possible. Data for the CEA was generated 191 
for points a and b performing 1500 iterations for every active surveillance component and design in 192 
all 24 standard population structures. Thus, for each of the 24 population structures we compared 193 
technical performance and costs from three components applied in five surveillance designs (RT-PCR, 194 
ELISA, BMT applied to design 1-4; and PCR only applied to design 5) in two points (a, b). 195 
Model sensitivity analysis 196 
Because some parameters can be influenced by policy, their effect on the technical performance of 197 
the various surveillance components (CSe) was assessed, namely farmer disease awareness (fDA), 198 
veterinary disease awareness (vDA), herd design prevalence (P*H) and within-herd design prevalence 199 
(P*A). As the CSe also depends on the population structure, model sensitivity was assessed for 200 
primarily meat producing and primarily milk producing populations. The range of investigated values 201 
is shown in Table 5. For each parameter value the stochastic distribution of CSe was computed with 202 
100 iterations. The kernel density (function kde2d{MASS} in R) , i.e. the frequency of CSe values was 203 
plotted in 3D as function of the changing parameter and the CSe value. Because production animals 204 
are routinely observed by their owners, model sensitivity of clinical surveillance was assessed first 205 
followed by clinical surveillance combined with diagnostic methods used within the active 206 
surveillance (RT-PCR, ELISA or BMT). 207 
 208 
Results 209 
Surveillance optimisation 210 
The number of herds and animals within a herd to reach the thresholds of 95 or 99% CSe were 211 
determined for three surveillance components (RT-PCR, ELISA and BMT) in 24 standard population 212 
structures. As an example, we report in Fig. 2 the analysis of a random sampling design (design 1) for 213 
populations dominated by dairy cattle in small and large herds, with 5% of the herds at risk (A and B 214 
in Fig. 2), populations dominated by dairy cattle in small and large herds, with 40% of the herds at 215 
risk (C and D), and populations dominated by beef cattle in small and large herds, with 5 % of the 216 
herds at risk (E and F). In this design, RT-PCR and ELISA required similar samples to reach 95 or 99% 217 
CSe, despite changes in dominating species, production type, or proportion at risk. As expected, BMT 218 
appeared only useful if the population was dominated by dairy type cattle (see Fig. 2 E and F).  Fig. 2 219 
is one example of the model output, and the corresponding plots for the remaining 18 standard 220 
populations are available as supplementary data. 221 
An alternative perspective is provided in Fig. 3, where BMT was compared amongst the four different 222 
surveillance designs in populations with small herds and 5% of the herds at risk. For design five, 223 
mandatory vaccination, neither BMT nor ELISA is suited, because both rely on antibody detection in 224 
milk and in blood, respectively. Fig. 3 shows that not only the dominating production type, but also 225 
the design had a significant effect on the median CSe reached with a given sample. 226 
Cost-effectiveness analysis 227 
Because clinical surveillance leaves little room for sampling optimisation, the cost-effectiveness 228 
analysis was only conducted on the different active surveillance designs. The points a (sampling as 229 
few animals within a herd as possible) and b (sampling as few herds as possible) were identified for 230 
every active component in each surveillance design to compute the total cost of the interventions 231 
and plotted in Fig. 4. Because the sampling procedure was chosen to achieve the threshold of at least 232 
95% CSe, all components are situated close to this threshold on the y-axis.  BMT did not achieve this 233 
threshold in a population structure with 70% meat production, but was most cost-effective in all 234 
other populations for the designs 1-4 (circles on the right side in Fig. 4). Furthermore, because the 235 
bulk milk surveillance was applied at herd level, it was also quite constant in cost, i.e. the cost of BMT 236 
was not very sensitive to the choice of surveillance design or population structure. Consistently, to 237 
substantiate freedom from BTV-8, ELISA surveillance was more expensive than BMT, but cheaper 238 
than RT-PCR surveillance, due to test costs and animal based sampling.  239 
Considering random sampling (design 1, black in Fig. 4) as baseline, design 3 (green in Fig. 4) 240 
generated only marginal differences in total costs for all corresponding surveillance components. The 241 
cost of vaccination was not taken into account. The range of total costs for surveillance was smallest 242 
for a sample targeted at high risk herds (design 2, red in Fig. 4), and widest for voluntary vaccination 243 
and sampling targeted at non-vaccinated herds at high risk (design 4, light blue in Fig. 4). The cost of 244 
the latter design was also the most sensitive to population structure. Compulsory vaccination with 245 
RT-PCR surveillance (design 5, dark blue in Fig. 4) was systematically more expensive than all other 246 
designs, albeit the cost of vaccination was not considered. Design 2 systematically generated the 247 
least costs compared to the baseline random design.  248 
In addition, it was more cost-effective to sample a minimal number of animals per herd (left side in 249 
Fig. 4) compared to sampling as few different herds as possible (right side in Fig. 4), because the 250 
information gained with an additional sample in the same herd was relatively poor, while an animal 251 
from a different herd contributed more at only slightly superior costs. This effect was minute for 252 
design two, sampling high risk herds, in meat producing populations with small herds. Conversely, 253 
design five, vaccination and sampling of non-vaccinated herds at high risk produced the largest cost 254 
divergence between the points a and b (dark blue  left and right in Fig. 4, respectively). This effect 255 
was more pronounced in populations with a large proportion at risk (compare A and B with C and D 256 
in Fig. 4). 257 
Finally, if one minute observation time per animal by farmers was accounted in the cost for clinical 258 
surveillance, the approximate annual costs in the simulated populations of 50,000 herds would arise 259 
to 500 million €. The veterinary follow-up and testing cost 0.01 million €, and the information 260 
campaign 0.02 million €.  261 
 262 
Model sensitivity analysis 263 
The median CSe for clinical surveillance was very close to one for the entire range of the investigated 264 
parameters, and for all population structures. The CSe was reduced only when the most likely fDA 265 
was set lower than 0.02, while vDA remained within the range defined in Table 1 (and Fig. 5). Since 266 
SeH, and hence CSe, is relative to the product of fDA and vDA (Equation 1) the same applies for vDA, 267 
i.e. the CSe for clinical surveillance remains at close to one as long as the product of fDA x vDA is 268 
larger than 0.00015, i.e. the combined probability that farmer and veterinarian detect and pursue 269 
the case. Fig. 6 shows the probability distribution of CSe depending on P*H when P*A is fixed at 270 
0.0001. The median CSe remains at one for values of P*H greater than 0.015 and reaches 0.5 for 271 
values at approximately 0.002. In reverse, CSe is insensitive to changes in P*A even with a P*H fixed as 272 
low as 0.01 (data not shown). Consequently, also any combination of active surveillance with clinical 273 
surveillance reached SSe approximating one with negligible 95% confidence intervals.  274 
 275 
Discussion 276 
Clinical surveillance 277 
In this study clinical surveillance was shown to detect bluetongue infections with almost 100% 278 
certainty. This is plausible because the period of observation was one year and infections with BTV-8 279 
cause a disease which is readily detectable by clinical observation (A.R.W. Elbers et al., 2008). The 280 
CSe of clinical surveillance was not sensitive to variations of disease awareness by farmers (fDA) or 281 
veterinarians (vDA) within a realistic range. The observation that CSe of clinical surveillance does not 282 
change upon perturbations of the design prevalence further emphasizes that this surveillance 283 
component is a high value source of information to declare freedom from disease and proves that 284 
the passive surveillance components such as clinical surveillance are of importance to exclude clinical 285 
infection. The presented results are even overestimating the effect of P*H on the CSe, as under 286 
natural conditions, infections are over-dispersed and hence P*A should be larger than P*H, in contrast 287 
to the parameters used here (Faes et al., 2011). Furthermore, the model assumes a specificity of 1, 288 
implying that every observation with symptoms suspicious for BTV-8 infection is pursued until it is 289 
confirmed with highest confidence. Concurrent diseases with similar clinical spectrum would 290 
therefore raise the confirmatory activity for false positive cases (and consequently the costs). These 291 
are contextual interactions, which do not affect more specific surveillance components such as ELISA 292 
or RT PCR. Nevertheless, the most cost-effective system to demonstrate freedom from disease is 293 
clinical surveillance. This reflects findings using other authors (Souza Monteiro et al., 2012; Welby et 294 
al., 2016), it should however be noted, that due to the modelling approach employed here, this is not 295 
necessarily true for alternative surveillance objectives, such as early detection or estimation of 296 
prevalence.  297 
The CSe of clinical surveillance might be overestimated due to methodological reasons; indeed, the 298 
conventional approach for calculating herd-level sensitivity (SeH) in scenario trees might not be 299 
entirely appropriate for clinical observations, because it assumes that all animals in a herd are 300 
equally subject to surveillance. Although biological heterogeneity in showing clinical signs is 301 
considered with a maximal sensitivity of 0.67 (A.R.W. Elbers et al., 2008), individual animals are 302 
unlikely to be evenly subjected to clinical observation for practical reasons. In fact, decisions about 303 
whether or not to call a veterinarian will often be taken based on information relevant at herd level 304 
rather than at animal level (Even Sergeant, pers. communication), and will further depend on 305 
willingness to report. Hadorn and co-workers considered these probabilities with additional factors 306 
for the probability to report in the Swiss surveillance system, and calculated a median sensitivity of 307 
0.924 (95% CI: 0.724-0.987) for clinical surveillance in 52,983 herds (Hadorn et al., 2009). This 308 
additional fraction in Equation 1 (morbidity x probability of reporting by farmer x probability of 309 
reporting by veterinarian), together with a lower pert distribution for the sensitivity of clinical signs 310 
and computation of the model at herd level, account for the different estimates. If in the present 311 
model the sensitivity of clinical observations would be assumed to operate at herd level, this would 312 
result in a maximum SeH of 0.67 (A.R.W. Elbers et al., 2008), which is considerably lower than the 313 
median SeH of  >0.99% that was computed. However, considering that from a veterinary service 314 
perspective, the total sensitivity of this surveillance component is aggregated for 50,000 herds, even 315 
this difference of SeH has only marginal effects on the total CSe.  316 
The actions induced by clinical surveillance cost 0.01 million € for case follow-up and 0.02 million € 317 
for the information campaign. For case follow-up, similar costs were predicted for a medium 318 
awareness level by Hadorn et al. (Hadorn et al., 2009). However, a retrospective analysis (Häsler et 319 
al., 2012) suggests that we over-estimated follow-up costs and sensitisation campaign by about 50%. 320 
Furthermore, we have considered one minute observation time per day and cow, which may be 321 
implicit in a milking procedure, but should be performed explicitly in fattening herds and young stock 322 
to reach the best possible sensitivity of clinical surveillance. Also depending on season and 323 
production system the quality of the observation may vary. At a labour cost of 15 €/ h and a 324 
simulated population of 1.5 million animals this time spent corresponds to an annual equivalent of 325 
approximately 500 million €. Although attribution of costs is a matter of policy, it is unusual to 326 
compensate the farming industry for surveillance efforts, to the extent that these costs have not 327 
even been reported in previous studies (Hadorn et al., 2009; Häsler et al., 2012). Also, because 328 
observation for health cannot be accounted independently of other husbandry activity, it is difficult 329 
to determine its true value. However, even if it this effort was considered as a specific activity, due to 330 
its syndromic focus, it would need to be divided among all notifiable diseases and ultimately 331 
considered in the socio-ecological context (Rich et al., 2013). 332 
Active surveillance  333 
Under the assumption that active surveillance was mandatory, the components assessed for active 334 
surveillance in this study were assumed to be implemented independently of clinical surveillance. 335 
The European Commission regulation 1266/2007 (European Commission, 2007) allows a flexible 336 
implementation of active surveillance:  a risk-based design can be implemented, and in terms of 337 
testing for BTV-8, bulk-tank milk testing, blood ELISA and RT-PCR are available (Hadorn et al., 2009; 338 
Vandenbussche et al., 2008). Risk based surveillance was most cost-effective if a small proportion of 339 
the population was at high risk. With an increasing proportion of the population at high risk the cost-340 
saving effect due to risk-based surveillance became smaller considering the same relative risk. 341 
However, because the size of the population at high risk and the relative risk are usually interrelated 342 
and influence each other mutually in addition to the actual cost-effect. Therefore, the result of 343 
modifying the population at risk by either strengthening the criteria or combining risk factors, will 344 
need to be assessed for each specific case. This should be considered when risk is defined to inform 345 
the policy. Also, the model doesn’t account for overlap between different surveillance components 346 
and thus may overestimate the number of detected cases and consequently the surveillance system 347 
sensitivity. The administration and planning of risk-based surveillance was not taken into account in 348 
this model and would thus be underestimated. In order to be more cost-effective than random 349 
sampling, this amount could arise to roughly 0.3 million € for 5% of the modelled population at risk, 350 
but only 0.2 million € for 40% at risk (Fig. 4). This further emphasises, that with a large population at 351 
high risk, risk-based surveillance is not necessarily cost-effective. 352 
Although the five surveillance designs investigated in this study were just a few of many possible 353 
options, the authors feel that they represent some fundamental choices that are made by policy 354 
makers. Bulk-tank milk testing was most cost-effective with relatively little variance of cost between 355 
designs, although its CSe varied depending on the choice of sampling design (Fig. 3). Moreover, it was 356 
not suited to attain a required threshold of 95% sensitivity for three designs (1, 3 and 5) when a 357 
proportion of 70% of the population were kept for meat rather than dairy production (Fig. 3). 358 
RT-PCR and blood serology using ELISA provided similar information at similar cost in populations 359 
where 5% of the herds were at high risk and risk-based surveillance was performed. However, with 360 
rising proportion at high risk (with constant relative risks), the costs of risk-based surveillance 361 
increased due to the larger sample size required. This amplified the four-fold higher costs for an RT-362 
PCR compared to an ELISA. These observations are primarily because the call-out fee of 65 € was 363 
equal for both regimes, while the difference in test costs of 9 € (ELISA) and 40 € (RT-PCR) had 364 
relatively little impact due to the comparably little added value of an additional sample in the same 365 
herd. In this context it appeared that sampling a maximal number of herds (point a) was most cost-366 
effective due to the fact, that one sample from a new herd added more information than a sample 367 
drawn from a herd that was already sampled. In the present model this compensated the additional 368 
cost of 65 € for the herd visit. It must be emphasised that the distinct capacities of RT-PCR and ELISA 369 
to detect antigens and antibodies, respectively, both contribute to evidence for freedom from BTV-8. 370 
They provide distinct supplementary information for surveillance for early detection or the 371 
assessment of prevalence or vaccination coverage. 372 
Voluntary vaccination with an assumed reduction of the susceptible herds by 10% and surveillance 373 
targeted at non-vaccinated herds only marginally reduced costs compared to random sampling. In 374 
contrast, mandatory vaccination with an assumed coverage of 75% reduced the cost of surveillance 375 
targeted at herds at high risk, particularly if this was only a small proportion of the population. These 376 
estimates considered surveillance costs only, and did not include the costs for vaccination. Therefore, 377 
the cost for vaccination justifiable with its effect on surveillance should not exceed the approximately 378 
400’000 € saved by the surveillance design 5 compared to the baseline random design (dark blue 379 
versus black in Fig. 4). Given the population of cattle of approximately 1.5 million this would justify a 380 
cost of 0.26 € per vaccine, bearing in mind that this only covers the cost of surveillance and not the 381 
benefits of vaccination preventing the disease. 382 
Conclusions 383 
Under the assumption that BTV-8 manifests clinically as described by Elbers et al. (A.R.W. Elbers et 384 
al., 2008), freedom from disease in a population can be established with almost certainty over the 385 
period of one year using clinical surveillance alone. Additional investment in active surveillance 386 
would therefore economically only be justified, if no clinical manifestation is suspected or other 387 
surveillance objectives are to be provided such as early detection. In the first case, the regulatory 388 
requirement of demonstrating freedom from disease is questionable since due to the lack of clinical 389 
manifestation, the economic importance arises only from the regulation and not from the disease. In 390 
the second case, surveillance is only cost-effective if the time gain and consequently smaller impact 391 
of a disease introduction compared to clinical surveillance alone, justifies the additional costs.  In this 392 
case it is important to realise that 1) this requires a high sampling frequency, 2) for emerging 393 
diseases diagnostic tools may not be available, 3) the risk estimation to target risk-based sampling 394 
may induce high uncertainty, and 4) scenario trees cannot provide reliable information on the time 395 
gain.  396 
With the legal requirement for active surveillance, risk-based surveillance to prove freedom from 397 
disease is only cost-effective if a small proportion of the population is at high risk. The best cost-398 
effectiveness is obtained by sampling the maximal number of herds rather than more animals per 399 
herd. This effect is expected to grow with increasing aggregation of infections within herds. The 400 
effect of mandatory vaccination against BTV-8 on surveillance justifies a cost of < 0.26 € per vaccine 401 
and voluntary vaccination only marginally reduces the cost of surveillance. Finally, bulk-tank milk 402 
testing is the method of choice to actively demonstrate freedom from disease in populations 403 
dominated by dairy production. 404 
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  490 
Tables 491 
Table 1. Parameters and input values used in the scenario tree model for Bluetongue surveillance 492 
in Europe. Variable or uncertain parameters were modelled stochastically as PERT distributions (with 493 
the three input values stated in the table), and otherwise fixed values were used. Where no 494 
references are given, estimates were based on combined expert opinions reported by Nafzger and 495 
co-workers (Nafzger, 2016). The time resolution of the scenario tree is one year. 496 
Parameter description Symbol Minimum Most likely Maximum 
Herd design prevalence1 P*H  0.002  
Within-herd design prevalence1 P*A  0.005  
Number of herds   50,000  
Herd size  1 30 or 100 400 
     
Morbidity due to BTV-8 in cattle2 morbc  0.025  
Farmer Disease Awareness in cattle3 fDAc 0.002 0.150 0.670 
Veterinary Disease Awareness in cattle3 vDAc 0.002 0.550 0.670 
Sensitivity PCR in cattle4 PCR-Sec 0.990 0.995 0.999 
Sensitivity ELISA in cattle4 ELISA-Sec 0.853 0.887 0.923 
Sensitivity BMT in cattle5 BMT-Sec  0.540  
     
Morbidity due to BTV-8 in sheep2 morbs  0.077  
Farmer Disease Awareness3 in sheep fDAs 0.044 0.200 0.760 
Veterinary Disease Awareness3 in sheep vDAs 0.044 0.600 0.760 
Sensitivity PCR in sheep4 PCR-Ses 0.990 0.996 0.999 
Sensitivity ELISA in sheep6 ELISA-Ses n.a. n.a. n.a. 
Sensitivity BMT in sheep6 BMT-Ses  n.a.  
1according to the current version of the EC 1266/2007 (European Commission, 2007) a prevalence of 497 
0.05 in the bovine population of the Member State must be detected by the surveillance system with 498 
95 % confidence. Prior to the amendment of 30th May 2012 (commission implementing regulation No 499 
456/2012) the detection of a prevalence of 0.005 was required. Hence, these design prevalences 500 
assumed in the present study are more stringent conditions than those currently implemented in the 501 
EU. 502 
2according to Elbers and co-workers (Armin R. W. Elbers et al., 2008). To compute the annual 503 
morbidity per animal, the observed mean number of sick cattle (2.1) and sheep (2.7) per herd was 504 
divided by the mean herd size (85.2 and 35.5, respectively). 505 
3Minimal disease awareness (DA) was 0.2% and 4.4% for cattle and sheep, respectively, while 506 
maximal DA corresponded to the sensitivity of clinical signs estimated by Elbers and co-workers and 507 
implemented by Welby et al. (A.R.W. Elbers et al., 2008; Welby et al., 2013). Most likely values were 508 
set at roughly ¼ of the range for farmers and ¾ for veterinarians to simulate their differing 509 
professional expertise. 510 
4according to Vandenbussche et al. (Vandenbussche et al., 2008). 511 
5according to the diagnostic test manufacturer (ID Vet, 2008). 512 
6 because in the scenario, no active surveillance in sheep was considered, these values were not 513 
used. 514 
 515 
  516 
Table 2. Costs in Euros for surveillance activity for Bluetongue surveillance. Estimates are based on 517 
the results of the questionnaire by Nafzger and co-workers (Nafzger, 2016) and the authors’ opinion 518 
to represent a western European average. The same costs applied to the cattle and the sheep 519 
population, however in the present study active surveillance was only performed on the cattle 520 
population as required by the EC regulation. The worksheet provided as supplementary material 521 
allows for time dependent compensation or flat rates, e.g. clinical examination, because we 522 
calculated with time-dependent payments, the flat rate fields are set at zero. 523 
 cost [Euros] unit cost 
Labour cost   
Farmer routine check 15 hour 
Veterinarian intervention 40 hour 
Abattoir worker 23 hour 
Lab. Technician 23 hour 
Epidemiologist/ senior scientist 60 hour 
Compensations   
Call-out fee veterinarian 65 visit 
Clinical examination vet. 0 sample 
Lab. Technician 0 sample 
Laboratory costs   
C-ELISA test 9 sample 
RT-PCR 40 sample 
Virus isolation 30 sample 
Immunohistochemistry 20 sample 
Sampling material (blood) 1 sample 
Miscellaneous costs   
Transportation incl. packaging 12 visit 
Communication of results 0 visit 
Cost of information campaign for farmers 20,000 population and year 
 524 
 525 
  526 
Table 3. Time expenditure in hours for different clinical and diagnostic activities as applied in the 527 
cost-effectiveness analysis. Estimates are based on the results of the questionnaire by Nafzger and 528 
co-workers (Nafzger, 2016) and the authors’ opinion to represent a western European average. The 529 
same costs applied to the cattle and the sheep population. For laboratory analyses also covered in 530 
Table 2 flat rates are employed, hence time expenditure is stated as zero, however, the worksheet 531 
provided as supplementary material also allows for time-dependent calculations. 532 
 hours unit 
Time for clinical visit   
Farmer routine check 0.02 animal and day 
Veterinarian intervention 0.04 animal 
Time for sampling   
Blood 0.08 sample 
Tissue 0.17 sample 
Milk 0.02 farm and day 
Time for lab. work and analysis   
ELISA 0 sample 
RT-PCR 0 sample 
Virus isolation 0 sample 
Immunohistochemistry 0 sample 
Epidemiological data analysis 1.00 farm and year 
 533 
  534 
Table 4. Combination of characteristics used for the 24 simulated population structures considered 535 
for the optimisation of BTV-8 surveillance. To compute a population, one option of each column are 536 
combined. The effect of population composition on surveillance component sensitivity (CSe) is 537 
reported in the results section.  538 
Cattle:Sheep X Dairy:Meat X Herd Size X Proportion at high risk 
70 : 30  70 : 30  S  5 % 
or  30 : 70  or  30 : 70  or  L   or  10 % 
      or  40 % 
 539 
  540 
Table 5. Parameters and their range used to analyse model sensitivity of BTV-8 surveillance 541 
scenario tree models. Dependence of surveillance component sensitivity (CSe) on the parameters is 542 
reported in the results section. 543 
Parameter name Symbol Minimum Maximum 
Median farmer disease awareness fDA 0.00 0.50 
Median veterinary disease awareness vDA 0.00 0.50 
Herd design prevalence P*H 0.00 0.04 
Within-herd design prevalence P*A 0.00 0.04 
 544 
 545 
Figures 546 
 547 
Fig. 1 Flowchart illustrating the structure of the scenario tree for an active surveillance component. Risk nodes (diamonds), 548 
infection nodes (rectangles) and detection nodes (rounded boxes) are set in sequence. Dashed lines indicate that a branch 549 
continues identically to the branch drawn in solid lines from that particular node. Perfect specificity (Sp=1) is assumed at 550 
the end of each branch and the probability of a positive outcome (black ellipse) is computed. 551 
 552 
 553 
 554 
Fig. 2 Surveillance sensitivity for random sampling (design 1). The plot reports the median of 500 iterations. It shows the 555 
median number of animals sampled in a herd (x-axis) and the median number of herds sampled (y-axis) in a population of 556 
50,000 herds to reach a surveillance sensitivity of 95% (light green) or 99% (dark green) for six population structures (the 18 557 
others are available as supplementary data). For each population structure, three active surveillance components were 558 
assessed blood RT-PCR assay (PCR), blood ELISA (ELISA) or bulk milk testing (BMT) with ELISA. The population structures 559 
considered were: A) a population composed of small herds (median 30 cows/herd) with 70% cattle and 30% sheep, 70% 560 
dairy and 30% meat production, where 5% of the population is at high risk of infection by BTV-8; B) a population composed 561 
the same as A), but with large herds (median 100 cows/herd); populations C) and D) have the same structure, but 40% are 562 
at risk, while in populations E) and F) again 5% are at risk, but 70% of the animals are in meat and 30% in dairy production. 563 
 564 
 565 
 566 
Fig. 3 Surveillance sensitivity for bulk milk testing (BMT) in populations composed of small herds with 5% at high risk of 567 
infection with BTV-8. The plot reports the median of 500 iterations. It  shows the median number of animals sampled in a 568 
herd (x-axis) and the median number of herds sampled (y-axis) in a population of 50,‘000 herds to reach a surveillance 569 
sensitivity of 95% (light green) or 99% (dark green). The plots on the left show the sensitivity for populations dominated by 570 
dairy cattle and the plots on the right populations dominated by beef production. The surveillance strategies considered 571 
were: design 1) random sampling, design 2) target on high risk herds, design 3) voluntary vaccination and target on non-572 
vaccinated herds, design 4) voluntary vaccination and target on non-vaccinated herds at high risk. Design 5, with 573 
mandatory vaccination is not suitable for BMT as the latter relies on detection of antibodies which are present in all 574 
vaccinated animals. 575 
 576 
Fig. 4 Comparison of sampling the least number of animals per herd (also referred to as “point a”, left) and sampling the 577 
least number of herds (also referred to as “point b”, right) in different population structures (letters A-F, see below). The y-578 
axis shows the median technical performance (component sensitivity, CSe) of the surveillance design and the x-axis the 579 
median total annual costs of 1500 iterations for the five surveillance designs: Random sampling (design 1, black), high risk 580 
targeting (design 2, red), voluntary vaccination and targeting non-vaccinated animals (design 3, green), voluntary 581 
vaccination and targeting non-vaccinated animals in high risk herds (design 4, light blue), and mandatory vaccination and 582 
RT-PCR in high risk herds (design 5, dark blue). The surveillance components are coded as shapes: RT-PCR (), ELISA () 583 
and BMT (). The component sensitivity was assessed in different population structures: A) a population composed of 584 
small herds (median 30 cows/herd) with 70% cattle and 30% sheep, 70% dairy and 30% meat production, where 5% of the 585 
population is at high risk of infection by BTV-8; B) a population composed the same as A), but with large herds (median 100 586 
cows/herd); populations C) and D) have the same structure, but 40% are at risk, while in populations E) and F) again 5% are 587 
at risk, but 70% of the animals are in meat and 30% in dairy production. 588 
 589 
 590 
Fig. 5. Kernel density (z-axis), i.e. the frequency of the component sensitivity (CSe, x-axis) of clinical surveillance depending 591 
on variation of farmer disease awareness in increments of 0.0001 (fDA, y-axis) in the Belgian setting as reported by Nafzger 592 
and co-workers (Nafzger, 2016). The two-dimensional kernel density estimation was performed with the function 593 
kde2d{MASS} in R, performing 1000 iterations for each fDA value. Veterinary disease awareness (vDA) was kept constant at 594 
0.01. Due to Equation (1), for any product of fDA*vDA greater than 0.00015, the CSe was converging towards one. 595 
 596 
Fig. 6. Kernel density (z-axis), i.e. the frequency of component sensitivity (CSe, x-axis) of clinical surveillance depending on 597 
the variation of herd design prevalence in increments of 0.0002 (P*H, y-axis) in the Belgian setting as reported by Nafzger 598 
and co-workers (Nafzger, 2016). The two-dimensional kernel density estimation was performed with the function 599 
kde2d{MASS} in R, performing 1000 iterations for each P*H value. Within-herd design prevalence (P*A) is fixed at 0.0001. 600 
Note that despite a modelled unnatural under-dispersion of infections, the mean CSe remains close to 1.0 from values 601 
greater than 0.15. As infections are naturally over-dispersed, CSe should be even less sensitive to changes in P*H. 602 
 603 
 604 
